Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-APEX: REGN7508 vs apixaban and enoxaparin for VTE prophylaxis after total knee arthroplasty
2025-520478-20-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of cenvacibart in venous thromboembolism (VTE) and thromboembolism (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Composite incidence of venous thromboembolism. Planned start Oct 2025; status: authorised.
02
Drugs
cenvacibart
03
Conditions
venous thromboembolism (VTE)thromboembolism
Beyond the preview
Go deeper on 2025-520478-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520478-20-00.